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Renal amyloid deposits can often be seen in primary
amyloidosis (immunoglobulin light chain disease) or in
secondary forms such as reactive amyloidosis as well as in
several hereditary forms where a variety of mutant proteins
‘precipitate’ as amyloid plaques. However, in rare cases,
amyloidosis may be identified by renal biopsy, but no
definitive diagnosis could be made. We have isolated amyloid
fibrils from such a case in which the patient presented with
nephrotic syndrome and subsequent azotemia requiring
hemodialysis. Evaluation for amyloid deposition in other
organ systems was negative and immunohistochemical
analysis of the kidney deposits for known contributing
proteins was unrevealing. Biochemical analysis of the fibrils
identified a new amyloid subunit protein, leukocyte
chemotactic factor 2, originally identified as a possible
chemotactic and growth factor. A monoclonal antibody to
this protein reacted specifically with the amyloid deposits in
the glomeruli and interstitium by immunohistochemistry.
This study emphasizes the importance of biochemical
characterization of amyloid present in renal biopsies.
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Renal amyloidosis is usually a manifestation of a systemic
disorder.1 The most common form of amyloidosis with renal
involvement is immunoglobulin light chain amyloidosis, the
result of a monoclonal plasma cell dyscrasia. Multisystem
involvement is the rule, and rarely is the kidney the sole site
of significant amyloid deposition. Reactive (secondary)
amyloidosis (AA) is much less common, but continues to
be a life-threatening outcome for patients with inflammatory
arthritis, regional enteritis, osteomyelitis, periodic fever
syndromes, and other chronic inflammatory diseases. In
AA, renal involvement is usually an early feature and the
most common cause of death. A number of hereditary forms
of amyloidosis have predominantly renal involvement with
either proteinuria or progressive azotemia. Amyloidosis
associated with mutations in fibrinogen Aa-chain,2 apolipo-
protein AI,3 apolipoprotein AII,4 and lysozyme5 usually
present with renal manifestations, although hepatic and
cardiac amyloid deposition may also be present. Hereditary
transthyretin amyloidosis may present with renal manifesta-
tions, but in a lesser percentage of affected individuals.6
Amyloidosis restricted to the kidneys is uncommon but, as
it usually presents with bilateral organ involvement indicat-
ing that the amyloid precursor protein is derived from the
blood, it must be considered a systemic form of the disease.
We describe a new form of renal amyloidosis due to fibril
formation from a protein not previously known to be
amyloidogenic.
RESULTS
Pathology
The resected kidney (10.8 4.8 4.5 cm) contained a well-
circumscribed 3.5 cm mass in the superior pole. Light
microscopy sections of the tumor revealed renal cell
carcinoma, clear cell type. Sections of the non-neoplastic
kidney revealed completely sclerosed glomeruli with amor-
phous pink acellular material on hematoxylin and eosin stain
(Figure 1). This amorphous material stained with Congo red
and gave green birefringence when viewed with polarized
light (Figure 2). Congo red-positive material was also present
in the blood vessel walls and interstitium. Electron micro-
scopy revealed linear nonbranching fibrils in the mesangium,
capillary walls, and throughout the subendothelial space
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(Figure 3). Immunofluorescence on frozen sections gave no
staining of amyloid deposits with either anti-k light chain or
anti-l light chain antisera. No staining was seen with anti-
amyloid A (AA) on either frozen or formalin-fixed tissue
sections (Figure 4). Indirect immunohistochemistry on both
frozen and formalin-fixed paraffin embedded sections with
anti-leukocyte cell-derived chemotaxin 2 (LECT2) antibody
gave strong staining of glomerular deposits. Staining was also
observed for vascular wall and interstitial deposits (Figure 5).
Biochemical analysis
Direct Edman sequence analysis of guanidine hydrochloride
solubilized material from the kidney specimen yielded a
sequence identical to the amino terminus of mature LECT2
protein (Figure 6). The first two residues could not be
identified due to high initial background levels of all amino
acids. Analysis on SDS-PAGE revealed three bands at
approximately 13, 15, and 17 kDa. After transfer to
polyvinylidene difluoride membrane, Edman analysis of the
13 and 17 kDa bands yielded no discernable sequence,
whereas the 15 kDa band yielded the amino-terminal
sequence of LECT2 (Figure 6). After trypsin digestion,
peptides isolated by reverse-phase HPLC gave sequences
as noted in Figure 6, which spanned the entire sequence
of the mature LECT2 protein. The residue 67–74 tryptic
Figure 1 | Section of kidney showing replacement of glomeruli
with amorphous eosinophilic material (hematoxylin and
eosin). Original magnification  100.
Figure 4 | Control sections of kidney showing no staining of
amyloid deposits with anti-AA monoclonal antibody. Original
magnification  40.
Figure 2 | Section of kidney stained with Congo red. (a) Congo
red-stained section of kidney with marked staining in glomeruli,
blood vessel walls, and interstitial tissues. Original magnification
 40. (b) When viewed under polarized light, Congo red-stained
deposits give green birefringence typical of amyloid.
Figure 3 | Electron microscopy of renal glomerulus showing
nonbranching fibrils (original magnification  4800). Average
diameter of fibrils is 10 nm (original magnification (inset)
 98 000).
Figure 5 | Section of frozen kidney treated with monoclonal
anti-LECT2 antibody showing localization to glomerular and
interstitial deposits. Formalin-fixed tissue sections gave similar
distribution of staining but was less intense. Original
magnification  100.
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peptide gave very low recoveries of residues 71–74 on Edman
analysis. This could be the result of isomerization of Asn71 to
an iso-Asp residue, which would be resistant to Edman
degradation.
DNA analysis
Direct DNA sequencing of exons 2, 3, and 4 of LECT2 using
primers from Table 1 revealed the nucleotide sequence as
published. DNA sequence of the patient’s peripheral blood
leukocyte DNA and DNA isolated from skin were identical.
Both revealed homozygosity for the G nucleotide (SNP rs
31517, exon 3) at the first position of codon 58 (amino acid
40 of the mature protein).
DISCUSSION
Leukocyte cell-derived chemotaxin 2 was originally isolated
and characterized from culture media of PHA-activated
human T-cell leukemia cells as part of studies to identify
chemotactic factors important in the pathophysiology of
neoplasia.7 Although the original characterization of LECT2
proved to be of bovine origin from the fetal calf serum used
in media, these studies led to the cloning and structural
characterization of the human analog.8 The protein was
independently characterized from fetal bovine cartilage and
named chondromodulin II.9 The human LECT2 gene is
localized to chromosome 5 (5q31.1–q32) and consists of four
exons and three introns.10 The gene codes for 151 amino
acids (MW 16 376 Da) including an 18 amino acid signal
peptide. The secreted protein has 133 residues. A poly-
morphism has been identified with either valine or isoleucine
at position 58, position 40 of the mature protein (codon
change GTC to ATC). Review of the NCBI SNP database
indicates that the G allele has an overall frequency of 0.477
and a frequency range of 0.6–0.7 in subjects of European
descent.
Northern blot analysis demonstrated that LECT2 is
expressed in adult and fetal liver, but not in other tissues.8
Immunohistochemistry with monoclonal antibody to
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Figure 6 | Amino-acid and nucleotide sequence of human LECT2. The residues of the mature protein after the 18 residue signal
peptide are numbered 1–133. The arrow labeled ‘Gu Sol’ denotes the sequence obtained from the guanidine hydrochloride soluble
sample. The X in positions 1 and 2 denote that the residue could not be identified due to high initial background levels of all amino
acids. The arrow labeled ‘15 kDa’ denotes the sequence obtained from the 15 kDa band on polyvinylidene difluoride. The dots
at the end indicate that the sequence continues but was not analyzed further. The other arrows indicate the sequences obtained
from analysis of HPLC fractions from a trypsin digest of the guanidine soluble material.
Table 1 | Primers used for PCR amplification of LECT2 gene
exons 2, 3, and 4
Exons Nucleotide Primer Sequence
2 2001–2240 E2-1: 50 GATAAGGCAAATGGGGATAGG 30
E2-2: 50 ACCAACGTTGGGCAAGGACA 30
3 3601–3895 E3-1: 50 TGTTCCCAGGCAGTAAAGCTC 30
E3-2: 50 TCTCTACGTATGGAACCTGCAT 30
4 7485–7777 E4-1: 50 CAGATTCAAGATTACTGAAGCCC 30
E4-2: 50 TTGAAGAGAAGGGTATGCATCC 30
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recombinant human LECT2 demonstrated positive localiza-
tion to human hepatocytes.11 Subsequent immunohisto-
chemistry studies have identified positive staining in many
tissues of the body, and it was hypothesized that LECT2
expression may be related to cell growth or repair after cell
damage.12 This hypothesis is consistent with studies demon-
strating that the protein is a cartilage growth factor
(chondromodulin II).
The discovery of LECT2 as an amyloid fibril protein is
similar to the story of many of the amyloid precursor
proteins including apolipoprotein-AI, fibrinogen Aa-chain,
apolipoprotein-AII, cystatin C, gelsolin (Gel), lysozyme,
serum amyloid A, b2-microglobulin, immunoglobulin light
chain, and the Ab protein of Alzheimer disease. Each was
initially identified by amino-acid sequence analysis of protein
extracted from tissue amyloid fibril deposits. In most cases,
the identity of the amyloid subunit protein has been a
surprise, despite the fact that practically all of the precursor
proteins had been well described previously as normal blood
or organ tissue proteins. An exception is serum amyloid A,
which was not recognized previously until its proteolytic
product AA was identified as a fibril protein in reactive
amyloidosis.13,14 Although a number of these amyloid
proteins have been demonstrated to have extensive b-
structure which is the hallmark of amyloid proteins
(immunogobulin light chain, b2-microglobulin, lysozyme),
a number of these (serum amyloid A, apolipoprotein-AI, and
apolipoprotein-AII) have not been shown to have significant
b-structure in their native state. Tertiary structure data for a
number of amyloid proteins including fibrinogen Aa-chain
are yet to be obtained. Most amyloid precursor proteins
undergo some degree of proteolysis before incorporation into
fibril structures. There are a few exceptions including
lysozyme and apolipoprotein-AII, and it would appear from
the present case that the entire secreted LECT2 protein is
incorporated into the amyloid fibril. Whether LECT2 has
significant b-structure in the native state or acquires this in
the process of forming amyloid fibrils must be the subject of
future studies.
Questions that remain to be answered include whether
LECT2 is an inducible protein and whether the amyloid
precursor is produced by the liver. LECT2 has been
reportedly measured at a serum level of approximately
30 ng ml1.12 The relationship of circulating levels of LECT2
to the formation of renal amyloid in the present case could
not be determined. The presence of LECT2 in the plasma of
the patient 2 years after nephrectomy, if present, was below
the level of detection by Western analysis with antibody to
LECT2.
Nucleotide sequencing studies of DNA obtained from the
patient’s peripheral blood leukocytes and from skin biopsy
tissue showed no mutation which might suggest an inherited
type of amyloidosis. The patient was homozygous for the G
allele, which is reported for approximately 60% of the
European population. We can hypothesize that LECT2
amyloidosis is an acquired condition perhaps related to
some unknown factor causing overexpression of this normal
protein. It will be interesting to see if the report of this new
amyloid protein leads to discovery of other patients with
LECT2 renal amyloidosis and, thereby, insight into the
pathogenesis of this type of amyloidosis.
METHODS
Patient
A 54-year-old woman presented with nephrotic syndrome. Renal
biopsy revealed glomerular deposition of amyloid. Evaluation for
systemic amyloidosis, including abdominal fat pad and colon and
skin biopsies, was negative. Serum creatinine slowly increased to
1.9 mg per 100 ml 3 years after the renal biopsy, and after
nephrectomy for renal carcinoma at age 61 (7 years after initial
presentation), dialysis became necessary. The resected kidney was
submitted for routine pathology. In addition, tissue for biochemical
analysis was frozen at 801C.
Isolation of amyloid protein
Amyloid fibrils were isolated from the nephrectomy specimen by a
modified procedure of Pras et al.15,16 Kidney tissue, approximately
0.5 cm each dimension, was minced with a razor, hand-homo-
genized in 0.1 M sodium citrate and 0.15 M sodium chloride, and
centrifuged. The pellet was homogenized and centrifuged two more
times. The final pellet was solubilized in 8 M guanidine hydro-
chloride, 0.5 M Tris (pH 8.2) containing 1 mg EDTA per ml, and
10 mg dithiothreitol per ml overnight. After alkylation with
iodoacetic acid and centrifugation, the supernatant was exhaustively
dialyzed against water and lyophilized.
Characterization of amyloid protein
The lyophilized guanidine hydrochloride soluble sample was
suspended in 10% acetic acid, and portions were dried in a speed
vac or lyophilized for further analysis. Samples were analyzed by
SDS-PAGE using the Tricine system of Scha¨gger and Von Jagow17
and electrophoretically transferred to polyvinylidene difluoride
membrane. Approximately half of the sample was digested with
trypsin in 0.1 M ammonium bicarbonate, and the resulting peptides
were fractionated by reverse-phase HPLC on a Beckman Ultrasphere
ODS column. Edman degradation analysis of samples was
performed on an Applied Biosystems Model 491 cLC protein
sequencer using the manufacturer’s standard cycles and methods.
Immunohistochemistry was performed by the indirect method
using monoclonal anti-LECT2 (R&D Systems Inc., Minneapolis,
MN, USA) as primary antibody (1:100 dilution) and horseradish
peroxidase-labeled anti-murine IgG as secondary antibody (1:200).
DNA isolation
Genomic DNA was isolated from peripheral blood using a standard
phenol/chloroform procedure.18 DNA was also isolated from skin
biopsy tissue of the patient.
Direct DNA sequence analysis
Exons 2, 3, and 4 of LECT2 were amplified using primers listed in
Table 1. PCR was performed in a total volume of 50 ml including
10 PCR buffer (500 mM KCl, 100 mM Tris-HCl, pH 8.3, 25 mM
MgCl2), 1ml of 10 mM dNTP mix, 0.25 mM of each primer, 1 U of Hot
Master Taq polymerase (Eppendorf, Hamburg, Germany) and 2 ml
DNA. Amplification was performed using a Peltier Thermal Cycler
PTC-100 (Bio-Rad, Hercules, CA, USA) for 30 cycles consisting of
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denaturing at 941C for 1 min, annealing at 621 for 1 min, and
extension at 721C for 1 min.
Amplified products were gel-purified using the Qiaquick Gel
Extraction Kit (Qiagen, Valencia, CA, USA) and subjected to
asymmetric amplification using the DTCS Quick Start Kit (Beckman
Coulter, Fullerton, CA, USA). Products were analyzed on a CEQ
8000 GeXP Genetic Analysis System (Beckman Coulter, Fullerton,
CA, USA). The resulting DNA sequences were compared with the
known LECT2 sequences (http://www.ncbi.nlm.nih.gov/).
Procedures in this report were conducted in accordance with the
ethical standards of the Helsinki Declaration of 1975 and as revised
in 1983.
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